All Industries

Top healthtech Companies

659 healthtech companies, sorted by total funding raised.

NANO-X IMAGING LTDIPO

Nanox develops FDA-cleared digital X-ray and 3D tomographic imaging systems with AI-based CT anal...

Neve Ilan, Israel201–500healthtech, Healthcare
Venture Unknown·$105.0M·Jul 2020
Scholar RockIPO

Scholar Rock is a biopharmaceutical company discovering and developing innovative medicines targe...

Cambridge, United States51–200Biotech, Healthcare
Series C·$103.0M·Jan 2018
Karyopharm Therapeutics Inc.IPO

Innovation-driven pharmaceutical company focused on discovery, development, and commercialization...

Newton, United States201–500healthtech, biotech
Series B·$102.2M·Jul 2013
Innate Pharma S.A.IPO

Global clinical-stage oncology-focused biotech company developing innovative cancer treatments to...

Marseille, France201–500healthtech, biotech
Corporate Round·$101.5M·Jun 2014
Dianthus TherapeuticsIPO

Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation comple...

New York, United States11–50healthtech, Biotech
Series A·$100.0M·Apr 2022
Iovance BiotherapeuticsIPO

Biotherapeutics company developing and commercializing tumor infiltrating lymphocyte (TIL) cell t...

San Carlos, United States501–1000healthtech, Biotech
Series B·$100.0M·Jun 2016
Structure TherapeuticsIPO

Clinical-stage biopharmaceutical company developing novel oral small molecule therapeutics for ch...

South San Francisco, United States51–200healthtech, biotech
Series B·$100.0M·Oct 2021
SELLAS Life Sciences GroupAcquired

Late-stage clinical biopharmaceutical company developing novel cancer immunotherapies targeting u...

New York, United States1–10healthtech, biotech
Corporate Round·$98.5M·Oct 2025
CarlsmedIPO

AI-enabled personalized spine surgery platform delivering patient-specific implants and surgical ...

San Diego, United States51–200Artificial Intelligence, Data & Analytics
Series C·$95.0M·Mar 2024
NovoCure LimitedIPO

Novocure is an oncology company developing Tumor Treating Fields (TTFields) therapy as a novel ca...

Saint Helier, Jersey1001–5000healthtech, Biotech
Venture Unknown·$95.0M·Jan 2015
Vanda Pharmaceuticals Inc.IPO

Vanda Pharmaceuticals (NASDAQ: VNDA) is a global biopharmaceutical company focused on the develop...

Washington, United States201–500healthtech, Biotech
Venture Unknown·$93.5M·Mar 2018
Trisalus Life SciencesIPO

Medical device company developing drug delivery technology for treating liver and pancreatic soli...

Westminster, United States51–200healthtech, medtech
Private Equity·$91.5M·Apr 2025
Cytokinetics, IncorporatedIPO

Late-stage biopharmaceutical company focused on discovering, developing, and commercializing firs...

South San Francisco, United States201–500healthtech, Biotech
Series C·$91.0M·Nov 2000
Amicus TherapeuticsIPO

Oral pharmacological chaperone protein therapies to address diseases that result from protein mis...

Cranbury, United States501–1000Biotech, Drug Discovery
Venture Unknown·$86.0M·Jan 2006
Ascendis Pharma A/SIPO

Clinical-stage biopharmaceutical company developing TransCon therapeutic platforms targeting rare...

Hellerup, Denmark501–1000healthtech, biotech
Series D·$85.7M·Dec 2014
Intellia TherapeuticsIPO

Leading clinical-stage genome editing company developing novel, potentially curative therapeutics...

Cambridge, United States201–500healthtech, biotech
Series B·$85.0M·Sep 2015
Larimar TherapeuticsIPO

Clinical-stage biotech developing treatments for complex rare diseases, with lead compound target...

Bala Cynwyd, United States51–200healthtech, biotech
Venture Unknown·$80.0M·May 2020
Fulcrum TherapeuticsIPO

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small molecule ther...

Cambridge, United States51–200healthtech, Biotech
Series B·$80.0M·Sep 2018
Autolus Therapeutics plcIPO

Clinical-stage biopharmaceutical company developing advanced CAR T cell therapies for the treatme...

London, United Kingdom51–200healthtech, Biotech
Series C·$80.0M·Sep 2017
Sight SciencesIPO

Medical technology company providing eyecare providers with transformative, clinically-proven the...

Menlo Park, United States201–500healthtech, Healthcare
Venture Unknown·$77.0M·Jan 2020
XencorIPO

Clinical-stage biopharmaceutical company developing XmAb-engineered antibodies and cytokines to t...

Pasadena, United States201–500healthtech, Biotech
Series A·$75.1M·Jun 2013
ARS PharmaceuticalsIPO

Develops and commercializes neffy, an FDA-approved needle-free epinephrine nasal spray for treati...

San Diego, United States51–200Healthcare, Therapeutics
Series D·$75.0M·Aug 2021
Precision BioSciencesIPO

Clinical-stage gene editing company developing in vivo therapies using its proprietary ARCUS geno...

Durham, United States51–200Biotech, Gene Editing
Venture Unknown·$75.0M·Jun 2022
Collegium PharmaceuticalIPO

Biopharmaceutical company committed to improving the lives of people living with serious medical ...

Stoughton, United States201–500healthtech, Biotech
Series D·$72.5M·Mar 2015
CadreIPO

Cadre is the first digital investment marketplace that provides access to institutional, quality ...

New York, United States51–200Fintech, Marketplace
Series C·$65.0M·Jun 2017